MedTrace Logo

A Cross-Sectional Observational Study on Retained Drug Needle Fragments in People Who Use Intravenous Drugs

NCT05679284 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2023-06-01

No results posted yet for this study

Summary

In addition to the well-known toxicological harms of intravenous drug (IVD) use, there can also be local tissue complications, including infections, venous sclerosis, tissue necrosis, and drug needle fragment retentions. Drug needle fragments in subcutaneous tissue may cause local symptoms (usually pain and infections), but they have also been identified as causing emboli to organs. The literature has described numerous case reports of people who inject drugs (PWIDs) and have retained needle fragments. The prevalence of the condition is not known, and the researchers therefore aim to perform the first cross-sectional study of PWIDs to estimate how common needle fragment retentions are and what their risk factors are in this population.

Conditions

  • Drug Abuse, Intravenous
  • Substance Dependence
  • Needle Injury
  • Soft Tissue Injuries
  • Foreign Bodies

Interventions

RADIATION

Low-dose X-ray of subcutaneous tissues

To identify needle fragment retentions, the radiologic imaging of all volunteers will be performed with X-ray using radiation doses as low as reasonably achievable (ALARA) and one projection per anatomic site.

Sponsors & Collaborators

  • Deaconess Foundation

    collaborator UNKNOWN

  • A-Clinic Foundation

    collaborator UNKNOWN

  • Tampere University Hospital

    lead OTHER

Principal Investigators

  • Otso Arponen, MD-PhD · Pirkanmaa Hospital District (PSHP)

  • Olli PO Nevalainen, MD-PhD · City of Tampere; Tampere University; Pirkanmaa Hospital District (PSHP).

  • Irina Rinta-Kiikka, MD-PhD · Tampere University Hospital

  • Heidi Laukkala, MD · City of Tampere, Tampere University

  • Markku Sumanen, MD-PhD · Tampere University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-25
Primary Completion
2027-11-15
Completion
2028-11-15

Countries

  • Finland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05679284 on ClinicalTrials.gov